Aileron Therapeutics, Inc. Receives $10,000,000 New Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7f91286a-bc43-4b8f-a265-b2ee079ed43c&Preview=1 -
Date
4/15/2008 -
Company Name
Aileron Therapeutics, Inc. -
Mailing Address
840 Memorial Drive Cambridge, MA 02139 -
Company Description
Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
for the treatment of cancer and other diseases. Aileron’s technology is the first and
only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs. -
Website
http://www.aileronrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$10,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
AILERON plans to use the proceeds from this financing to expand its drug discovery team and to open a 10,000+ square foot “Stapled Peptide” research facility located at 840 Memorial Drive in Cambridge, Massachusetts. -
M&A Terms
-
Venture Investor
Apple Tree Partners -
Venture Investor
Novartis BioVenture Fund
